Navigation Links
Early infusion of donor T cells prevents graft versus host disease in blood cancer patients
Date:2/3/2011

this study, which enrolled 22 patients with acute myeloid leukemia (AML), five patients with acute lymphoid leukemia (ALL), and one patient with high-grade non-Hodgkin lymphoma. Four days before HSCT, the 28 patients were infused with donor Tregs, and on the day of the transplant, they were infused with normal T cells in an effort to simultaneously prevent GVHD and promote immune system recovery.

"Our aim was to determine if patient outcomes could be improved if Tregs were introduced early in the transplantation process," said senior study author Massimo F. Martelli, MD, Full Professor and Head of the Umbria Region Bone Marrow Transplantation Program at the University of Perugia.

Results of the study revealed that 26 patients achieved full-donor engraftment, meaning that all of the transplanted donor cells were able to reproduce into new, cancer-free cells. Only two of the 26 patients that were evaluated developed acute GVHD, and at median follow-up of 11.2 months none of the patients had developed chronic GVHD. The immune system of these patients was restored to normal levels, better than other patients who had not received the T cell infusions. There were also fewer episodes of the reactivation of Cytomegalovirus (CMV), a common virus known as a major cause of morbidity and mortality after HSCT due to a weakened immune system, and no patient developed CMV disease. Furthermore, early Treg infusion was not associated with an increased incidence of leukemia relapse; only one relapse had occurred at median follow-up of 12 months in a patient with AML. One patient died from adenoviral infection and GVHD and one died from GVHD; at median follow-up of 12 months, 12 patients (46.1 percent) were alive and disease-free.

"This is an update of the first study in humans that demonstrates that regulatory T cell-based therapy ensures that hematopoietic stem cell transplant is successful, without triggering GVHD, by reconstituting the patient's immun
'/>"/>

Contact: Lindsey Love
webmaster@hematology.org
202-552-4925
American Society of Hematology
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Early Puberty Onset Linked to Stronger Bones
2. Early detection of lung cancer
3. Ritalin may ease early iron deficiency damage
4. PET scans may allow early prediction of response to targeted therapy of thyroid cancer
5. New 10-year study confirms too many pitches strike out youth athletes early
6. Voice-saver: Light therapy for early-stage laryngeal cancer
7. Ancient Toolkit Holds Clues to Migration of Early Man
8. Yearly mammograms from age 40 save 71 percent more lives, study shows
9. High Rates of Early Elective Delivery at Some U.S. Hospitals: Report
10. Unrealistic optimism appears common in early cancer trials
11. Nearly Half of Americans Still Suspect Vaccine-Autism Link
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... York (PRWEB) , ... July ... ... attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now available ... 2015 was well received with a 94% approval rating from the nationwide ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their ... involvement and support of animal welfare organizations is essential to the longevity of their ... year in the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets ...
(Date:7/31/2015)... ... ... Transfinder, a software company based in Schenectady, N.Y., achieved record revenue for ... the first six months ended June 30, 2015 compared with the same period in ... record-revenue mark of $10.4 million. , “We know what our customers need and want ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t ... the industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International ... event attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... firm, has been recognized in the 2015 Aster Awards national competition for a ... organization serving Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
... Dinoire’s countenance has changed 360 degrees in comparison to how ... the first patient in the world to undergo a// partial ... year ago, combined the dexterity of a 50 member team, ... has recovered very well. ,Miss Dinoire, 39, ...
... Maldives men's volleyball team lost to Chinese Taipei (Taiwan) in ... three of its players were confirmed to have chicken// pox. ... Asian Volleyball Confederation (AVC) said in a statement. ... pox. The disease spreads easily and we have to make ...
... in Mumbai suffers from backache, caused mainly by the poor ... out by Health India, a New Delhi-based non-profit group, the ... Delhi and 77 percent in Mumbai who use public transport ... ,"Bad roads, overcrowded public transport systems, poor quality of ...
... revealed that first time ecstasy users may suffer impaired memory and ... areas of the brain. , ,'We do not know if ... the University of Amsterdam, who led the study. 'Therefore, we cannot ... brain, and people should be informed of this risk.' ...
... the United Kingdom concluded that the UK's National Health ... least// for now. The review was published in the ... series of the Health Technology Assessment Programme, part of ... Kingdom. ,An implantable pump can help heart ...
... you hate being told to sit upright by others, because ... indeed what suits your// body better. Sitting ramrod straight may ... team of Scottish radiologists presented their findings recently at Chicago.They ... monitored using a specialized MRI scanner that could record their ...
Cached Medicine News:Health News:Maldives Volleyball Team Members Affected by Chickenpox 2Health News:Public Transport Causing Backaches in Delhi, Mumbai 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 3
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... July 30, 2015 Eisai Inc. announced today ... the United States , European Union and ... MHLW, respectively) for eribulin, for the treatment of patients ... prior chemotherapy for advanced or metastatic disease. ... a pivotal global Phase 3 clinical trial (Study 309), ...
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... DIEGO, March 21, 2012  Millennium Laboratories announced today ... the course for more responsible and ethical business ... outlines the principles to which Millennium adheres and ... in the pain management industry to adopt. ...
... encourages continuous electronic monitoring, including the use of both ... analgesia (PCA). According to the Institute ... knowledge exist today to prevent errors associated with use ... says , "The solutions are available. We know ...
Cached Medicine Technology:Millennium Laboratories Announces Laboratory Responsibility Pledge 2Millennium Laboratories Announces Laboratory Responsibility Pledge 3Physician-Patient Alliance for Health & Safety: Hospitals Need to Address PCA Pump Patient Safety 2
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... sulfate (DHEA-S) is the sulfate ester of ... enzymatic conversion of DHEA in adrenal and ... steroid secreted by the adrenal cortex, and ... biosynthesis. DHEA possesses relatively weak androgenic activity, ...
... DSL's unique DHEA-S-7kits ... antiserum targeted against the ... DHEA-S molecule, with no ... DHEA-S Saliva RIA has ...
... is based on the competition principle and ... DHEA-S present in the sample and a ... peroxidase compete for the binding sites of ... wells. After one hour incubation the microtiterplate ...
Medicine Products: